Published on Sep 1, 2020
LSI's Medtech Start-Up Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
OneDrop receives additional funding from Bayer, strengthening their collaboration
OneDrop is a digital health platform that utilizes 13 billion health data points to manage diabetes, cholesterol, and high blood pressure. The platform has over 2.5 million users worldwide. To-date the company has raised over $88M. Key competitors include Abbott, Dexcom, and Livongo.
Artificial-intelligence-powered image analysis software is in development at See-Mode Technologies
AVA (Augmented Vascular Analysis) uses artificial intelligence to individually analyze vascular ultrasound images and assist physicians in predicting a patient’s risk of stroke. The company recently completed a Series A round in August 2020; having raised $9M from the contributions of five investors. Other strategics in the ultrasound and image analysis market include Philips, RapidAI, and Viz.ai.
Flosonics Medical is developing and commercializing wearable sensors for critically ill patients
The company’s wearable sensor, FloPatch, allows for real-time functional hemodynamic monitoring of patients needing cardiopulmonary and fluid resuscitation. In August 2020 Flosonics completed a round of Seed funding valued at approximately $1M, bringing the total amount raised to-date by the company to approximately $6M. Key competitors in the critical care monitoring market include Draeger, Getinge, and Schiller.
Podimetrics raises $8M in recent Series B round
The August 2020 round was funded from investments from Polaris Partners, Rock Health, Norwich Ventures, and Scientific Health Development Partners. Podimetrics has obtained FDA 510(k) clearance for its SmartMat, a patient monitoring device capable of detecting and ultimately preventing the progression of diabetic foot ulcers. The company has raised over $28M to-date.
Advanced Medical Devices using a novel biomaterial are in development at Monarch Biosciences
The company is developing two medical devices using thin-film nitinol (TFN) technology. The first product is the Titan Flow Diverter, a flow diverting stent for the treatment of intracranial aneurysms. The second product in Monarch Biosciences’ pipeline is the Engineered Lymph Node, a TFN-based device designed to locally deliver cellular therapies to solid tumors. Key strategics include Boston Scientific, Edwards Lifesciences, and Medtronic.
InterShunt is developing a transcatheter solution to reduce the symptoms of heart failure
The InterShunt percutaneous atrial shunt catheter system reduces left atrial pressure and by extension, the symptoms of heart failure by capturing and excising tissue from the interatrial septum. InterShunt Technologies was part of the Summer 2018 gBeta Medtech accelerator program, which is supported by Boston Scientific, the Mayo Clinic, the University of Minnesota, and the Medical Alley Association.
AtriAN Medical – treating atrial fibrillation with micro pulsed electric fields (mPEF)
The company is developing technology developed at the Mayo Clinic. The technology uses non-thermal energy to target and ablate the hyperactive sites on the surface of the heart. AtriAN has raised approximately $2.7M. Major competitors in the atrial fibrillation devices market include AtriCure, BIOTRONIK, and Medtronic.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Start-Up Tracker.
LSI's global events attract top innovators, active investors, and deal-making strategics.GET INFO